MR imaging intensity modeling of damage and repair in multiple sclerosis: Relationship of short-term lesion recovery to progression and disability

American Journal of Neuroradiology

Volumn 28, Issue 10, 2007, Pages 1956-1963

  Meier, Dominik S ^a   Weiner, H L ^b   Guttmann, C R G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; PENTETIC ACID;

ARTICLE; ATROPHY; BRAIN DAMAGE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE;

ATROPHY; BRAIN; CONTRAST MEDIA; DISEASE PROGRESSION; GADOLINIUM DTPA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS;

EID: 36448957593     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: 10.3174/ajnr.A0701     Document Type: Article

References (28)

1. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-85
2. Brex PA, Ciccarelli O, O'Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158-64
3. Frohman EM, Filippi M, Stuve O, et al. Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Arch Neurol 2005;62:1345-56
4. Rudick RA, Lee JC, Simon J, et al. Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study. Ann Neurol 2006;60:236-42
5. Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl JMed 2000;343:1430-38
6. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-46
7. He J, Grossman RI, Ge Y, et al. Enhancing patterns in multiple sclerosis: evolution and persistence. AJNR Am J Neuroradiol 2001;22:664-69
8. van Waesberghe JH, van Walderveen MA, Castelijns JA, et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol 1998;19:675-83
9. Bagnato F, Jeffries N, Richert ND, et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain 2003;126:1782-89
10. Weiner HL, Guttmann CR, Khoury SJ, et al. Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage. J Neuroimmunol 2000;104:164-73
11. Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain 2000;123:2256-63
12. Filippi M, Rovaris M, Iannucci G, et al. Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 2000;55:1714-18
13. Prineas JW, Kwon EE, Cho ES, et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 2001;50:646-57
14. Patrikios P, Stadelmann C, Kutzelnigg A, et al. Remyelination is extensive in a subset of multiple sclerosis patients [published erratum appears in Brain 2007;130:879[. Brain 2006;129:3165-72
15. Lassmann H. Recent neuropathological findings in MS - implications for di-agnosis and therapy. J Neurol 2004;251 Suppl 4:IV2-5
16. Meier DS, Guttmann CR. MRI time series modeling of MS lesion development. Neuroimage 2006;32:531-37
17. Meier DS, Guttmann CR. Time-series analysis of MRI intensity patterns in multiple sclerosis. Neuroimage 2003;20:1193-209
18. Wei X, Warfield SK, Zou KH, et al. Quantitative analysis of MRI signal abnormalities of brain white matter with high reproducibility and accuracy. J Magn Reson Imaging 2002;15:203-09
19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52
20. Cotton F, Weiner HL, Jolesz FA, et al. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003;60:640-46
21. Lucchinetti C, Brück W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-17
22. Barkhof F, Bruck W, De Groot CJ, et al. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol 2003;60:1073-81
23. Schmierer K, Scaravilli F, Altmann DR, et al. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 2004;56:407-15
24. Willoughby EW, Grochowski E, Li DK, et al. Serial magnetic resonance scan ning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol 1989;25:43-49
25. Schwartz M, Kipnis J. Protective autoimmunity and neuroprotection in inflammatory and noninflammatory neurodegenerative diseases. J Neurol Sci 2005;233:163-66
26. Keegan M, König F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005;366:579-82
27. Barkhof F, Karas GB, van Walderveen MA. T1 hypointensities and axonal loss. Neuroimaging Clin N Am 2000;10:739-52, ix
28. van Waesberghe JH, Kamphorst W, De Groot CJ, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999;46:747-54